Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Atezolizumab Plus Tiraglolumab in Combination With Chemoradiotherapy in Localized Squamous Cell Carcinoma of the Anal Canal

NCT05661188 is registered in ClinicalTrials.gov with Grupo Espanol Multidisciplinario del Cancer Digestivo as lead sponsor.

NCT NCT05661188
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05661188 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Atezolizumab Plus Tiraglolumab in Combination With Chemoradiotherapy in Localized Squamous Cell Carcinoma of the Anal Canal
Lead sponsor
Grupo Espanol Multidisciplinario del Cancer Digestivo
Phase
Phase 2
Overall status
Completed
Start date
February 14, 2023
Completion date
September 25, 2026
Enrollment
45 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

squamous cell carcinoma of the anal canal